Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Oxid Med Cell Longev ; 2017: 1672567, 2017.
Article in English | MEDLINE | ID: mdl-28408969

ABSTRACT

The main objective of this research was to determine whether a commercial orange juice rich in anthocyanins could have an effect on body weight and on clinical parameters related to obesity including antioxidant status, lipid profile, and metabolic and inflammatory biomarkers. 11 women with an average BMI of 34.4 ± 4.8 kg/m2 were enrolled in a pilot study. Over a period of 12 weeks they received 500 mL daily dose into two doses (250 mL) of commercial red orange juice (COJ). The biochemical parameters were measured at baseline and at the end of the study (12 weeks). One month later upon free diet, a follow-up was performed measuring the same variables. The daily consumption of 500 mL of COJ had no significant effects on body weight, while there was a decrease in total cholesterol and LDL cholesterol. The grade of obesity implies different changes in inflammation biomarkers. In obese women, our data do not seem to support evidence that commercial red orange juice consumption acts as functional food preventing obesity and metabolic disorders such as insulin resistance and/or inflammatory status.


Subject(s)
Beverages/analysis , Citrus sinensis/chemistry , Obesity/prevention & control , Overweight/prevention & control , Adult , Anthocyanins/pharmacology , Biomarkers/analysis , Body Mass Index , Body Weight/drug effects , Cholesterol/blood , Cholesterol, LDL/blood , Citrus sinensis/metabolism , Female , Hemodynamics/drug effects , Humans , Nutritional Status , Pilot Projects
2.
Int J Food Sci Nutr ; 65(5): 637-45, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24611636

ABSTRACT

This study aims at investigating the effect of an experimental period of intake of whole grain foods rich in lignans as part of an habitual diet on the plasma and urinary excretion of enterolignans, the biomarkers of lipid metabolism and the immunological and antioxidant status in a group of postmenopausal women with moderate serum cholesterol. A randomized double-blind crossover study was completed on 13 subjects in 12-weeks after protocol approval of an ethical committee. The subjects consumed whole grain foods high in lignans (30 g/d of breakfast cereals or biscuits, etc., 80 g/d of whole grain pasta) or refined grain foods for 4 weeks, separated by a 2-weeks wash-out period. A modest hypocholesterolemic effect (p < 0.05) of the whole grain diet was observed and the intake of whole grain products rich in lignans was also associated with an increase in urinary enterodiol excretion (p < 0.05).


Subject(s)
Cholesterol/blood , Edible Grain/chemistry , Lignans/administration & dosage , Postmenopause , Blood Pressure , Body Mass Index , Body Weight , Cross-Over Studies , Diet , Double-Blind Method , Female , Glutathione Peroxidase/blood , Humans , Interleukin-1beta/blood , Interleukin-6/blood , Italy , Lignans/urine , Middle Aged , Pilot Projects , Superoxide Dismutase/blood , Tumor Necrosis Factor-alpha/blood
3.
J Endocrinol Invest ; 32(6): 542-5, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19494717

ABSTRACT

OBJECTIVE: To investigate whether MS is associated with erectile dysfunction (ED) among obese non diabetic individuals. METHODS: A cross-sectional study was carried out to examine the association between the cluster of abnormalities related to the MS and ED as evaluated by the International Index of Erectile Function (IIEF). Fifty consecutive obese [i.e. body mass index (BMI) > or =30 kg/m2], nondiabetic whites (age 42.1+/-11.3 yr, BMI 43.3+/-8.7 kg/m2) were recruited. RESULTS: The prevalence of MS as well as that of any MS component were not different between subjects with or without ED. Neither the prevalence of ED (34.3% vs 33.4%, p=0.6), nor IIEF score (21.5+/-3.9 vs 21.7+/-3.7, p=0.8), were different between patients with or without MS. IIEF was similar across subgroups of individuals stratified according to the number of MS components and was not related to HOMAIR index. Hypogonadism was observed in 30.8% and 28.1% individuals with and without MS (p=0.58). Testosterone and BMI levels were inversely related (r=-0.3, p=0.04). CONCLUSION: Among obese non-diabetic individuals the risk of developing ED is independent of the presence of MS factors. Testosterone levels progressively decrease with increasing body weight.


Subject(s)
Erectile Dysfunction/complications , Metabolic Syndrome/complications , Obesity/complications , Adult , Blood Glucose/metabolism , Body Mass Index , Cross-Sectional Studies , Erectile Dysfunction/blood , Erectile Dysfunction/physiopathology , Humans , Insulin/blood , Male , Metabolic Syndrome/blood , Metabolic Syndrome/physiopathology , Obesity/blood , Obesity/physiopathology , Surveys and Questionnaires , Testosterone/blood
4.
J Endocrinol Invest ; 25(11): 967-70, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12553556

ABSTRACT

The aim of this study was to analyze the serum levels of activin A in hyperthyroid patients with Graves' disease. Serum activin A and FSH levels were measured in a total of 93 females (64 regularly cycling and 29 post-menopausal). Of these, 20 were hyperthyroid patients with Graves disease, 33 were euthyroid goitrous patients (20 had autoimmune thyroiditis AT and 13 only had goiter) representing the internal control group and 40 were healthy subjects representing the external control group. Serum levels of activin A were higher in goitrous patients with AT than in control subjects (p=0.0388). Activin A levels were almost doubled in the cycling and in post-menopausal hyperthyroid women (0.91+/-0.21 vs 0.43+/-0.07 microg/l; p<0.0001 and 0.92+/-0.22 vs 0.48+/-0.24 microg/l; p=0.0001, respectively). In 10 cycling hyperthyroid patients, studied even after methimazole treatment, that increase was substantially reversed, once euthyroidism was attained (p=0.002). These findings indicate that thyroid function and autoimmune processes significantly affect serum levels of activin A in patients with Graves' disease.


Subject(s)
Activins/blood , Graves Disease , Graves Disease/blood , Inhibin-beta Subunits/blood , Adult , Aged , Autoantibodies/blood , Female , Follicle Stimulating Hormone/blood , Graves Disease/drug therapy , Graves Disease/immunology , Humans , Methimazole/therapeutic use , Middle Aged , Postmenopause , Thyrotropin/blood , Thyroxine/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...